Balance sheet
5/5very strongHow well the company can cover its financial obligations.
Net cash 296.98 m $, no net debt · Current ratio 3.20
Iovance Biotherapeutics, Inc.
IOVA · Quote currency USD · Closing price of 23 Oct 2026, grades from the latest annual report
Overview
Quality
–of 20
No quality points
Growth: no grade because data is missing. Nothing is estimated.
Price vs. its own range
–
No range
The share count in the annual report (357.35 k) does not match the cover page of the latest filing (452.97 m). Until the next data run the page therefore shows no range.
What drives the result
- Net cash 296.98 m $, no net debtBalance sheet: 5 of 5 thresholds
- Operating margin −153.1%Profitability: 0 of 5 thresholds
- Free cash flow to revenue −127.6%Cash flow: 0 of 5 thresholds
The four grades
Balance sheet5/5very strong
Profitability0/5no threshold reached
Cash flow0/5no threshold reached
Growth—/5no grade
What this means. The quality points show how many of the published rules for balance sheet, profitability, cash flow and growth the latest reports meet. Separately, the range shows how the latest closing share price compares with the company’s own valuation history.
What it does not mean. Neither the points nor the range is a price target, a forecast or a recommendation to buy or sell. A company with many points can be richly valued, and a price below its range often has a reason.
Next with this company
Watch
When a new report changes a grade, Pro tells you why. You do not have to check every report yourself.
Watchlist and alertsCompare
Other companies in Health care, analysed under the same rules. With Plus you filter by grades and figures and put them side by side.
Companies in Health careCheck
Every figure with its five thresholds and the rounding to the grade. With a free account for every company, over 5 years.
To the calculation
Quality
The four grades and how they are calculated
All values come from the annual reports filed with the US Securities and Exchange Commission (SEC). Each figure is checked against five fixed thresholds; each threshold reached counts one point. The grade is the rounded mean of its figures.
Profitability
0/5no threshold reachedHow effectively it turns revenue into operating profit.
Operating margin −153.1% · Return on equity −56.0%
Cash flow
0/5no threshold reachedHow much cash remains after operating costs and investment.
Free cash flow to revenue −127.6% · Profit covered by cash flow not reported · Free cash flow positive 0 of 5 years
Growth
—/5How quickly revenue and operating profit have increased.
Insufficient data: no grade. It is not estimated.
What is behind each grade
Every figure with its five thresholds, the distance to the next one and the rounding to the grade. With a free account: email only, no payment details.
Keep reading for freeIndustry
Compared with its industry
The comparison is within the SEC industry “Biological Products, (No Diagnostic Substances)”. Grades are absolute and are not adjusted to the industry: in a weak industry a weak grade stays weak.
More quality points do not mean a company is the better investment, only that more quality rules are met. It says nothing about the price.
Valuation
The price against its own history
No range is reported for this company. The share count in the annual report (357.35 k) does not match the cover page of the latest filing (452.97 m). Until the next data run accounts for it, the page shows no multiples and no range rather than wrong ones.
Financials
The figures over the years
Every figure comes from the annual report of that year and has not been revised afterwards. Amounts in USD. Negative net debt means more cash than financial debt.
More than a snapshot
Revenue, earnings and cash flow by fiscal year show how steadily the company performs. With a free account over 5 years.
Keep reading for freeCompetitive strengths
How durable the advantage is
0 of 6 points, measured over 10 years (2016 to 2025). Classification: no trace. These points are not part of the quality points.
| Feature | Points | Measured |
|---|---|---|
| Return on capital, level | 0/3 | The company earns on average −44.1% of its assets per year as operating profit, measured over 10 years. Comparable companies are around 10%. |
| Return on capital, consistency | 0/3 | 0 of 10 years above 10%. Consistency is the real evidence, because anyone has one good year. |
| Pricing power | —/2 | Gross profit is not reported separately in the filing. |
| Stability in a downturn | —/2 | The financial years 2020 and 2022 fall outside the window. |
What is measured is the trace of a moat: a durably high return on capital and margins that survive a downturn. The causes (switching costs, network effects, brand, licences, economies of scale) appear in no filing and are not claimed here.
Next figures: expected on 5 Nov 2026 (estimated from the rhythm of earlier filings, ± 21 days). Grades can change after a report; the page is then rebuilt.
New at the SEC
What the company filed most recently
Filings with the US Securities and Exchange Commission, newest first, in plain words. Insider purchases and sales only when they took place on the market; grants and tax withholding are not listed. Every entry links to the filing.
- 5 Oct 2026Reported another event8-K
- 29 Sep 2026Reported another event8-K
- 7 Aug 2026Major holder reports a stake above 5 %, as a passive investmentSCHEDULE 13G
Every filing of the last twelve months
19 more entries. With Pro, plus an alert when a new report changes a grade on your watchlist.
Discover ProHistory
When grades changed
See when something changed
When each grade changed and why, since the first analysis. With Pro, plus an alert for each new report that changes a grade on your watchlist.
Discover ProHow the company developed over time
Every earlier analysis with its date: quality points, the four grades, position against the range and how many companies had fewer points that day. With Plus.
Discover PlusSources
Sources and data status
| Company figures | Annual reports filed with the US Securities and Exchange Commission (SEC), machine-readable version (XBRL). Not estimated, not smoothed. |
|---|---|
| Prices | Daily closing prices from EOD Historical Data (EODHD) in USD, not converted. Price date 23 Oct 2026, closing price of that trading day. |
| Latest filing | 10-Q, 6 Aug 2026 |
| Rule set | Version 2.8.0 |
| Time horizon | The grades describe a state that can change with every annual report, so roughly quarterly. The historical test is computed over 36 months. |
| Editor | Florian Maier |
| Produced on | 24.10.2026 18:41 |
| Conflicts of interest | see the transparency note |
Not investment advice and not an investment recommendation. Limits of the method and assumptions: risk notice.